Table 4. . Correlation of p16 and p53 expression with clinico-pathological features of patients.
| Characteristics | p16 | p53 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADCs (n = 75) | SQCCs (n = 88) | ADCs (n = 75) | SQCCs (n = 88) | |||||||||
| (+) | (−) | p-value | (+) | (−) | p-value | (+) | (−) | p-value | (+) | (−) | p-value | |
| Age (years) | 0.414 | 0.106 | 0.409 | 0.966 | ||||||||
| <60 | 11 | 14 | 14 | 16 | 16 | 9 | 19 | 11 | ||||
| ≥60 | 27 | 23 | 17 | 41 | 27 | 23 | 37 | 21 | ||||
| Gender | 0.907 | 0.227 | 0.713 | 0.61 | ||||||||
| Male | 19 | 19 | 23 | 35 | 21 | 17 | 18 | 12 | ||||
| Female | 19 | 18 | 8 | 22 | 22 | 15 | 38 | 20 | ||||
| Pathological stage | 0.14 | 0.526 | 0.165 | 0.853 | ||||||||
| pT1 | 23 | 14 | 10 | 14 | 21 | 16 | 17 | 7 | ||||
| pT2 | 14 | 18 | 7 | 21 | 21 | 11 | 17 | 11 | ||||
| pT3 | 1 | 4 | 9 | 16 | 1 | 4 | 15 | 10 | ||||
| pT4 | 0 | 1 | 5 | 6 | 0 | 1 | 7 | 4 | ||||
| Differentiation grade | 0.108 | 0.291 | 0.139 | 0.619 | ||||||||
| Well | 7 | 2 | 0 | 4 | 3 | 6 | 2 | 2 | ||||
| Moderate | 26 | 25 | 23 | 37 | 33 | 18 | 37 | 23 | ||||
| Poor | 5 | 10 | 8 | 16 | 7 | 8 | 17 | 7 | ||||
| Smoking status | 0.166 | 0.933 | 0.726 | 0.007‡ | ||||||||
| Nonsmoker | 10 | 5 | 4 | 7 | 8 | 7 | 11 | 0 | ||||
| Smoker† | 28 | 32 | 27 | 50 | 35 | 25 | 45 | 32 | ||||
| EGFR/KRAS status | 0.736 | – | 0.286 | – | ||||||||
| Nonmutation | 34 | 32 | – | – | 36 | 30 | – | – | ||||
| Mutation | 4 | 5 | – | – | 7 | 2 | – | – | ||||
| mOS (months) | 60.9 | 46.9 | 0.048‡ | 40.7 | 49.5 | 0.19 | 54.1 | 54.0 | 0.846 | 48.4 | 42.9 | 0.701 |
†
Include both current and former smokers.
‡
Indicates p < 0.05, considered statistically significant.
ADC: Adenocarcinoma; mOS: Median overall survival time; SQCC: Squamous cell carcinoma.